Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2009;40:1858-1863
Published online before print March 12, 2009, doi: 10.1161/STROKEAHA.108.535765
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/5/1858    most recent
STROKEAHA.108.535765v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okauchi, M.
Right arrow Articles by Xi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okauchi, M.
Right arrow Articles by Xi, G.
Related Collections
Right arrow Acute Cerebral Hemorrhage

(Stroke. 2009;40:1858.)
© 2009 American Heart Association, Inc.


Original Contributions

Effects of Deferoxamine on Intracerebral Hemorrhage-Induced Brain Injury in Aged Rats

Masanobu Okauchi, MD; Ya Hua, MD; Richard F. Keep, PhD; Lewis B. Morgenstern, MD Guohua Xi, MD

From the Department of Neurosurgery (M.O., Y.H., R.F.K., L.B.M., G.X.) and the Stroke Program (R.F.K., L.B.M., G.X.), University of Michigan, Ann Arbor, Mich.

Correspondence to Guohua Xi, MD, R5018, BSRB, University of Michigan, Ann Arbor, MI 48109-2200. E-mail guohuaxi{at}umich.edu

Background and Purpose— Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats. In the present study, we investigated whether DFX is effective on brain injury after ICH in aged rats and examined dose dependency.

Methods— Male Fischer 344 rats (18 months old) had an intracaudate injection of 100 µL autologous whole blood and were treated with different doses of DFX (10, 50, and 100 mg/kg) or vehicle 2 and 6 hours post-ICH and then every 12 hours up to 7 days. Rats were euthanized at Day 3 for brain edema determination and Day 56 for brain atrophy measurement. Behavioral tests were performed during the experiments.

Results— All 3 doses of DFX attenuated perihematomal brain edema at 3 days (eg, at dose 50 mg/kg, 80.4±0.5 versus 81.6±0.9% in the vehicle-treated group, P<0.01). Fifty and 100 mg/kg DFX also reduced ICH-induced ventricle enlargement, caudate atrophy, and ICH-induced neurological deficits in aged rats. However, although 10 mg/kg DFX reduced ventricle enlargement and forelimb-placing deficits, it did not reduce caudate atrophy and corner turn deficits.

Conclusions— These results indicate that DFX can reduce ICH-induced brain injury in aged as well as young rats and that a dose >10 mg/kg is the optimal dose of DFX in this model.


Key Words: brain atrophy • cerebral hemorrhage • deferoxamine • iron